---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-003838"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:23:48.313322+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma Q1 revenue up 18% to $8.9M; net loss narrows

## Summary
- Revenue of $8.9 million in Q1 2025, up 18% from $7.5M in Q1 2024.
- Net loss improved to $1.18M from $1.28M in prior-year quarter.
- Appointed Michel Roy as new Chief Commercial Officer.
- Launched 6 new generic drugs: two antibiotics, two GI drugs, two schizophrenia drugs.
- Completed preclinical studies confirming K1.1 mRNA-LNP activity against hepatocellular carcinoma.

## SEC filing metadata
- accession: 0001683168-25-003838
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316825003838/0001683168-25-003838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316825003838/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-003838
- JSON: https://secwatch.observer/filing/0001683168-25-003838.json
- Plain text: https://secwatch.observer/filing/0001683168-25-003838.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.